{"id":"https://openalex.org/W2899208802","doi":"https://doi.org/10.1007/s11095-018-2519-x","title":"Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation","display_name":"Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation","alternate_titles":[],"publication_year":2018,"publication_date":"2018-10-29","ids":{"openalex":"https://openalex.org/W2899208802","doi":"https://doi.org/10.1007/s11095-018-2519-x","mag":"2899208802","pmid":"https://pubmed.ncbi.nlm.nih.gov/30374744","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6208585"},"language":"en","primary_location":{"id":"doi:10.1007/s11095-018-2519-x","doi":"https://doi.org/10.1007/s11095-018-2519-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11095-018-2519-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11095-018-2519-x.pdf","source":{"id":"https://openalex.org/S103865650","display_name":"Pharmaceutical Research","issn_l":"0724-8741","issn":["0724-8741","1573-904X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutical Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2899208802"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s11095-018-2519-x.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076973398","display_name":"Gerard A. Rodrigues","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139498","display_name":"Allergan (United States)","ror":"https://ror.org/03pfqk412","country_code":"US","type":"company","lineage":["https://openalex.org/I2948728702","https://openalex.org/I4210139498"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gerard A. Rodrigues","raw_affiliation_strings":["Biological Research, Allergan plc,, Irvine, California, 92612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Research, Allergan plc,, Irvine, California, 92612, USA","institution_ids":["https://openalex.org/I4210139498"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Lutz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139498","display_name":"Allergan (United States)","ror":"https://ror.org/03pfqk412","country_code":"US","type":"company","lineage":["https://openalex.org/I2948728702","https://openalex.org/I4210139498"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David Lutz","raw_affiliation_strings":["Biological Research, Allergan plc,, Irvine, California, 92612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Research, Allergan plc,, Irvine, California, 92612, USA","institution_ids":["https://openalex.org/I4210139498"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101642115","display_name":"Jie Shen","orcid":"https://orcid.org/0000-0002-2779-079X","observed_orcids":["https://orcid.org/0000-0002-2779-079X"]},"institutions":[{"id":"https://openalex.org/I4210139498","display_name":"Allergan (United States)","ror":"https://ror.org/03pfqk412","country_code":"US","type":"company","lineage":["https://openalex.org/I2948728702","https://openalex.org/I4210139498"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jie Shen","raw_affiliation_strings":["Nonclinical and Translational Sciences, Allergan plc,, Irvine, California, 92612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nonclinical and Translational Sciences, Allergan plc,, Irvine, California, 92612, USA","institution_ids":["https://openalex.org/I4210139498"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081802911","display_name":"Xiaoda Yuan","orcid":"https://orcid.org/0000-0002-7938-5083","observed_orcids":["https://orcid.org/0000-0002-7938-5083"]},"institutions":[{"id":"https://openalex.org/I4210139498","display_name":"Allergan (United States)","ror":"https://ror.org/03pfqk412","country_code":"US","type":"company","lineage":["https://openalex.org/I2948728702","https://openalex.org/I4210139498"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Xiaoda Yuan","raw_affiliation_strings":["Pharmaceutical Development, Allergan plc,, Irvine, California, 92612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development, Allergan plc,, Irvine, California, 92612, USA","institution_ids":["https://openalex.org/I4210139498"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011240907","display_name":"Hong Shen","orcid":"https://orcid.org/0000-0003-2185-4825","observed_orcids":["https://orcid.org/0000-0003-2185-4825"]},"institutions":[{"id":"https://openalex.org/I4210139498","display_name":"Allergan (United States)","ror":"https://ror.org/03pfqk412","country_code":"US","type":"company","lineage":["https://openalex.org/I2948728702","https://openalex.org/I4210139498"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hong Shen","raw_affiliation_strings":["Pharmaceutical Development, Allergan plc,, Irvine, California, 92612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development, Allergan plc,, Irvine, California, 92612, USA","institution_ids":["https://openalex.org/I4210139498"]}]},{"author_position":"middle","author":{"id":null,"display_name":"James Cunningham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139498","display_name":"Allergan (United States)","ror":"https://ror.org/03pfqk412","country_code":"US","type":"company","lineage":["https://openalex.org/I2948728702","https://openalex.org/I4210139498"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"James Cunningham","raw_affiliation_strings":["Pharmaceutical Development, Allergan plc,, Irvine, California, 92612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Development, Allergan plc,, Irvine, California, 92612, USA","institution_ids":["https://openalex.org/I4210139498"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079351919","display_name":"Hongwen M. Rivers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Hongwen M. Rivers","raw_affiliation_strings":["Allergan plc,, 2525 Dupont Drive, Irvine, California, 92612-1531, USA. rivers_hongwen@allergan.com","Pharmaceutical Development, Allergan plc,, Irvine, California, 92612, USA. rivers_hongwen@allergan.com","Allergan plc,, 2525 Dupont Drive, Irvine, California, 92612-1531, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allergan plc,, 2525 Dupont Drive, Irvine, California, 92612-1531, USA. rivers_hongwen@allergan.com","institution_ids":[]},{"raw_affiliation_string":"Pharmaceutical Development, Allergan plc,, Irvine, California, 92612, USA. rivers_hongwen@allergan.com","institution_ids":[]},{"raw_affiliation_string":"Allergan plc,, 2525 Dupont Drive, Irvine, California, 92612-1531, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5079351919"],"corresponding_institution_ids":[],"apc_list":{"value":4690,"currency":"USD","value_usd":4690},"apc_paid":{"value":4690,"currency":"USD","value_usd":4690},"fwci":5.4438,"has_fulltext":true,"cited_by_count":139,"citation_normalized_percentile":{"value":0.97954071,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"35","issue":"12","first_page":"245","last_page":"245"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.9814000129699707,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.9814000129699707,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10250","display_name":"Glaucoma and retinal disorders","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/topical-drug-delivery","display_name":"topical drug delivery","score":0.8679999709129333},{"id":"https://openalex.org/keywords/posterior-segment-of-the-eye","display_name":"posterior segment of the eye","score":0.9509999752044678},{"id":"https://openalex.org/keywords/ocular-drug-delivery","display_name":"ocular drug delivery","score":0.9309999942779541},{"id":"https://openalex.org/keywords/preclinical-to-clinical-translation","display_name":"preclinical to clinical translation","score":0.843999981880188},{"id":"https://openalex.org/keywords/ranibizumab","display_name":"ranibizumab","score":0.921999990940094},{"id":"https://openalex.org/keywords/aflibercept","display_name":"aflibercept","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/neovascular-age-related-macular-degeneration","display_name":"neovascular age-related macular degeneration","score":0.9800000190734863},{"id":"https://openalex.org/keywords/intravitreal-injection-alternatives","display_name":"intravitreal injection alternatives","score":0.925000011920929},{"id":"https://openalex.org/keywords/animal-model-selection","display_name":"animal model selection","score":0.8169999718666077},{"id":"https://openalex.org/keywords/small-animal-models","display_name":"small animal models","score":0.597000002861023},{"id":"https://openalex.org/keywords/feasibility-assessment","display_name":"feasibility assessment","score":0.4779999852180481}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8072159290313721},{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.7959098815917969},{"id":"https://openalex.org/C113520495","wikidata":"https://www.wikidata.org/wiki/Q2359854","display_name":"Posterior segment of eyeball","level":2,"score":0.707628071308136},{"id":"https://openalex.org/C2778749236","wikidata":"https://www.wikidata.org/wiki/Q4689286","display_name":"Aflibercept","level":4,"score":0.6836882829666138},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.658379077911377},{"id":"https://openalex.org/C2781270358","wikidata":"https://www.wikidata.org/wiki/Q5885594","display_name":"Holy Grail","level":2,"score":0.6300832033157349},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.5701067447662354},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5610954761505127},{"id":"https://openalex.org/C2779820397","wikidata":"https://www.wikidata.org/wiki/Q1392806","display_name":"Drug delivery","level":2,"score":0.5116444230079651},{"id":"https://openalex.org/C2779742858","wikidata":"https://www.wikidata.org/wiki/Q180609","display_name":"Intravitreal administration","level":3,"score":0.483782023191452},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.44976386427879333},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3835143446922302},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33922797441482544},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2539428472518921},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.13496151566505432},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.12125802040100098},{"id":"https://openalex.org/C2780827179","wikidata":"https://www.wikidata.org/wiki/Q422001","display_name":"Retinal","level":2,"score":0.11291942000389099},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C136764020","wikidata":"https://www.wikidata.org/wiki/Q466","display_name":"World Wide Web","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000069579","descriptor_name":"Ranibizumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000069579","descriptor_name":"Ranibizumab","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000287","descriptor_name":"Administration, Topical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005123","descriptor_name":"Eye","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D057170","descriptor_name":"Translational Research, Biomedical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058449","descriptor_name":"Intravitreal Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s11095-018-2519-x","doi":"https://doi.org/10.1007/s11095-018-2519-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11095-018-2519-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11095-018-2519-x.pdf","source":{"id":"https://openalex.org/S103865650","display_name":"Pharmaceutical Research","issn_l":"0724-8741","issn":["0724-8741","1573-904X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutical Research","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5166990","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6208585","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6208585","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6208585/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharm Res","raw_type":"Text"},{"id":"pmid:30374744","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30374744","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutical research","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s11095-018-2519-x","doi":"https://doi.org/10.1007/s11095-018-2519-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s11095-018-2519-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s11095-018-2519-x.pdf","source":{"id":"https://openalex.org/S103865650","display_name":"Pharmaceutical Research","issn_l":"0724-8741","issn":["0724-8741","1573-904X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutical Research","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2899208802.pdf","grobid_xml":"https://content.openalex.org/works/W2899208802.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W225597385","https://openalex.org/W1568901762","https://openalex.org/W1571702913","https://openalex.org/W1749875967","https://openalex.org/W1966662116","https://openalex.org/W1982173939","https://openalex.org/W1996978908","https://openalex.org/W2004304399","https://openalex.org/W2005025849","https://openalex.org/W2019889336","https://openalex.org/W2029230396","https://openalex.org/W2033275722","https://openalex.org/W2038688360","https://openalex.org/W2047399850","https://openalex.org/W2062098889","https://openalex.org/W2072011053","https://openalex.org/W2091209369","https://openalex.org/W2103517914","https://openalex.org/W2107027855","https://openalex.org/W2126886911","https://openalex.org/W2134161293","https://openalex.org/W2276006088","https://openalex.org/W2335891183","https://openalex.org/W2612951191","https://openalex.org/W2757751679","https://openalex.org/W2786125814"],"related_works":["https://openalex.org/W4206202146","https://openalex.org/W3178291841","https://openalex.org/W2948815053","https://openalex.org/W1966662116","https://openalex.org/W2896415494","https://openalex.org/W4294953489","https://openalex.org/W2126886911","https://openalex.org/W2147842670","https://openalex.org/W3011522762","https://openalex.org/W7134937539"],"abstract_inverted_index":{"Topical":[0],"delivery":[1,70],"of":[2,8,15,51,71,80,104,129],"therapeutics":[3],"to":[4,38,57,77,92,100,120],"the":[5,9,12,52,65,78,81],"posterior":[6],"segment":[7],"eye":[10,82],"remains":[11],"\"holy":[13],"grail\"":[14],"ocular":[16,109],"drug":[17],"delivery.":[18],"As":[19],"an":[20],"example,":[21],"anti-vascular":[22],"endothelial":[23],"growth":[24],"factor":[25],"biologics,":[26],"such":[27],"as":[28],"ranibizumab,":[29],"aflibercept,":[30],"and":[31,74,95,111,126],"bevacizumab,":[32],"are":[33,60],"delivered":[34],"by":[35],"intravitreal":[36,58],"injection":[37,59],"treat":[39],"neovascular":[40],"age-related":[41],"macular":[42],"degeneration":[43],"and,":[44],"although":[45],"these":[46],"drugs":[47],"have":[48,67],"revolutionized":[49],"treatment":[50],"disease,":[53],"less":[54],"invasive":[55],"alternatives":[56],"desired.":[61],"Multiple":[62],"reports":[63],"in":[64,83],"literature":[66],"demonstrated":[68],"topical":[69],"both":[72],"small":[73,84],"large":[75],"molecules":[76],"back":[79],"animal":[85,105],"models.":[86],"Despite":[87],"this":[88],"progress,":[89],"successful":[90,130],"translation":[91],"larger":[93],"species,":[94],"ultimately":[96],"humans,":[97],"has":[98],"yet":[99],"be":[101],"demonstrated.":[102],"Selection":[103],"models":[106],"with":[107,114],"relevant":[108,123],"anatomy":[110],"physiology,":[112],"along":[113],"appropriate":[115],"experimental":[116],"design,":[117],"is":[118],"critical":[119],"enable":[121],"more":[122],"feasibility":[124],"assessments":[125],"increased":[127],"probability":[128],"translation.":[131]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2899208802","counts_by_year":[{"year":2026,"cited_by_count":17},{"year":2025,"cited_by_count":18},{"year":2024,"cited_by_count":21},{"year":2023,"cited_by_count":16},{"year":2022,"cited_by_count":19},{"year":2021,"cited_by_count":23},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":7},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2018-11-09T00:00:00"}
